Inari PEERLESS II RCT Will Compare FlowTriever Versus Anticoagulation in PE Patients
May 22, 2023—Inari Medical, Inc. announced the planned enrollment of PEERLESS II, the company’s third randomized controlled trial (RCT) in
Thomas Jefferson University United States Nordrhein Westfalen University Of Pennsylvania Bernhard Gebauer Thomas Tu
Source: evtoday.com